Literature DB >> 1931757

Effects of combined use of class I antiarrhythmic agents on Vmax of guinea-pig ventricular muscles.

J Toyama1, T Kawamura, I Kodama.   

Abstract

The effects of the combined use of class-I antiarrhythmic drugs on the resting potentials (RP), amplitude of action potential (AMP), and Vmax of the action potential were investigated in guinea-pig ventricular papillary muscles that were superfused with oxygenated Krebs-Ringer solution at 35 degrees C. Disopyramide (40 microM) reduced Vmax to 68.6 +/- 3.1% (mean +/- SE, n = 5) of the control with minimal changes in RP and AMP when preparations were stimulated at 1 Hz. The addition of mexiletine (20 microM) to the solution containing disopyramide (40 microM) caused a minimal reduction of Vmax (less than 5%) for the stimulation of 1 Hz, but a significant reduction of Vmax (13% p less than 0.05) when stimulation was increased to 2 Hz. This amount of the reduction is compatible with that obtained by mexiletine alone, suggesting a simple additive Na+ channel inhibition by this drug combination. This additive effect was also observed in the recovery process of Vmax from the use-dependent block induced by train stimuli at 1 Hz. Flecainide (5 microM) reduced Vmax to 58.6 +/- 13.3% (n = 5). The addition of mexiletine to the superfusate with flecainide produced a further depression of 14 +/- 2.6% of Vmax, even at 1 Hz. This depression was larger than that produced by mexiletine, suggesting a synergistic action of the two drugs on the Na+ channel. Such information about the interaction of the class I drug combinations with the Na+ channel may be clinically important.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931757     DOI: 10.1007/bf00120828

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  14 in total

1.  Electropharmacologic synergism with mexiletine and quinidine.

Authors:  H J Duff; F D Kolodgie; D M Roden; R L Woosley
Journal:  J Cardiovasc Pharmacol       Date:  1986 Jul-Aug       Impact factor: 3.105

2.  Use-dependent blocking action of newly developed lidocaine-analogs on maximum rate of rise of action potentials in guinea pig papillary muscle.

Authors:  J Toyama; I Kodama; T Kusunoki; T Ishihara; Y Hattori; K Yamada
Journal:  Jpn Heart J       Date:  1987-03

Review 3.  Combination antiarrhythmic drug therapy for ventricular tachyarrhythmias.

Authors:  A M Greenspan; S R Spielman; L N Horowitz
Journal:  Pacing Clin Electrophysiol       Date:  1986-07       Impact factor: 1.976

4.  Comparison of the antiarrhythmic efficacy of disopyramide and mexiletine against stimulus-induced ventricular tachycardia.

Authors:  G Breithardt; L Seipel; R R Abendroth
Journal:  J Cardiovasc Pharmacol       Date:  1981 Sep-Oct       Impact factor: 3.105

Review 5.  Combination therapy for cardiac arrhythmias.

Authors:  S Lévy
Journal:  Am J Cardiol       Date:  1988-01-15       Impact factor: 2.778

6.  Mexiletine-quinidine combination: electrophysiologic correlates of a favorable antiarrhythmic interaction in humans.

Authors:  H J Duff; L B Mitchell; D Manyari; D G Wyse
Journal:  J Am Coll Cardiol       Date:  1987-11       Impact factor: 24.094

7.  Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea pig ventricular action potentials by mexiletine, disopyramide, and encainide.

Authors:  T J Campbell
Journal:  J Cardiovasc Pharmacol       Date:  1983 Mar-Apr       Impact factor: 3.105

8.  Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle.

Authors:  L M Hondeghem; T Matsubara
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

9.  Nonlinear relation between Vmax and INa in canine cardiac Purkinje cells.

Authors:  M F Sheets; D A Hanck; H A Fozzard
Journal:  Circ Res       Date:  1988-08       Impact factor: 17.367

10.  Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.

Authors:  A M Greenspan; S R Spielman; C R Webb; N M Sokoloff; A P Rae; L N Horowitz
Journal:  Am J Cardiol       Date:  1985-08-01       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.